Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

NCT02683941 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
77
Enrollment
INDUSTRY
Sponsor class

Stopped National Comprehensive Cancer Network \& European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment.

Conditions

Interventions

Sponsor

Ipsen